Sotac Pharmaceuticals

Sotac Pharmaceuticals Forward P/E

Forward P/E-forhold for Sotac Pharmaceuticals (SOTAC.NS) pr. 23. okt. 2026 er 17,21. I foregående år var Forward P/E-forhold 38,59 — en ændring på -55,41 % (lavere).

Forward P/E

17,21

YoY

-55,41%

Senest opdateret:

Forward P/E-forhold for Sotac Pharmaceuticals er 2025 17,21 . Forward P/E-forhold for Sotac Pharmaceuticals var 2024 38,59 . Det falder dermed med -55,41% lavere sammenlignet med året før.

Sotac Pharmaceuticals Forward P/E historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

Forward P/E
Dato
Forward P/E
1. jan. 2020
1.578,57 INR
1. jan. 2021
-58,39 INR
1. jan. 2022
47,98 INR
1. jan. 2023
30,73 INR
1. jan. 2024
38,59 INR
1. jan. 2025
17,21 INR
Sotac Pharmaceuticals Forward P/E historik
ÅRForward P/EYoY
17,21-55,41%
38,59+25,60%
30,73-35,97%
47,98-182,17%
-58,39-103,70%
1.578,57—

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Få en gratis API-nøgle

Sotac Pharmaceuticals Aktieanalyse

Hvad laver Sotac Pharmaceuticals? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Sotac Pharmaceuticals aktie

Forward P/E-forhold for Sotac Pharmaceuticals er 17,21 i 2025.

Forward P/E-forhold for Sotac Pharmaceuticals ændrede sig fra 38,59 til 17,21, hvilket repræsenterer en ændring på -55,41 %. Værdien er lavere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Forward P/E-forhold Sotac Pharmaceuticals siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

Forward P/E bruger estimeret fremtidig indtjening til at værdiansætte en aktie. Et lavere forward P/E i forhold til bagudrettet P/E tyder på, at analytikere forventer vækst i indtjeningen.

For at evaluere Forward P/E-forholds er det afgørende at sammenligne det med andre virksomheder i samme branche og sektor. På Eulerpool kan du finde branchsammenligninger for Forward P/E-forhold.

En 'god' varierer efter branche og virksomhedens udviklingsstadium. På Eulerpool kan du sammenligne Forward P/E-forholds Sotac Pharmaceuticals med konkurrenter og branchegjennemsnittet for at afgøre, om den er attraktiv.

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Få en gratis API-nøgle

Værdiansættelse — Sotac Pharmaceuticals

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/OmsætningEV/EBITDAEV/FCFIndtjeningsudbytteFCF-udbytteMarkedsværdiVirksomhedsværdiForward P/EP/TBVAktionærafkastAktietilbagekøbsafkastDiv.-justeret PEGEV/OCF

Alle nøgletal — Sotac Pharmaceuticals